Ostarine (MK-2866,Enobosarm)Merck presented the results of a phase2 clinical trial evaluatingOstarine (MK-2866),an investigational SARM in patients withcancer induced muscle loss,also known as cancer cachexia at theEndocrine Society Annual Meeting in Washington in 2009 [40].In this study 159 cancer patients with non-small cell lung cancer,
Open Acc J Repro & Sexual Disord Copyrights@ Michael AB Naafs.4/7Citation: Michael AB N. Selective Androgen Receptor Modulators (SARMs): A Mini-Review. Open Acc J Repro & Sexual Disord 1(1) - 2018. OAJRSD.MS.ID.000103.colorectal cancer, non-Hodgkins lymphoma, chronic lymphocyticleukemia or breast cancer were randomized. Participants receivedplacebo,1mg or 3mg Ostarine daily for 16 weeks. Average weightloss prior to entry was 8,8 percent and patients were allowed toreceive standard chemotherapy during the trial.
The drop-out rateduring the trial was 33%.Ostarine treatment led to statistically significant increases inlean body mass (LBM) and improvement in muscle performancemeasured by stair climbing in patients with cancer cachexiacompared to baseline in both the Ostarine 1mg and 3mg cohorts.In the study Ostarine met the primary endpoint of LBM mesured byDEXA(dual energy x-ray absorptiometry) scan, by demonstratingsignificant increases in LBM compared to baseline in both theOstarine 1mg and 3mg treatment was o,1kg(p=0,874 compared tobaseline, 1,5kg(p=0,001) and 1,3 kg(p=0,0045) at the end of the 16week trial.
The study also met the secondary endpoint of muscle functionas measured by a 12 step stair climbing test measuring speed andcalculating power with each Ostarine treatment arm demonstratinga statistically significant average decrease in time to completionand average percentage increase in power exerted.The change frombaseline in stair climb power in the placebo,1mg,and 3mg treatmentgroups was 0,23 Watts (p=0,66,compared to baseline)8,4Watts(p=0,002) and 10,1 Watts (p=0,001),respectively. A criticalappraisal results in the same critics,as depicted for the Ligandrolresults. Ostarine is also known as Enobosarm and S-22 SARM byvarious licensing contracts in the body building world.Ostarine had already shown significant improvement in theability of healthy,elderly men and women to climb stairs in aphase2A study in 2007.
Elderly men and women improved climbingstairs in speed and power,accompanied by significant increases inLBM and decreases in fat mass after only 86 days [41]. Enobasarm(GTx-024,Ostarine and S-22) is the most well characterizedclinically and has consistently demonstrated increases in LBM andbetter physical function across several populations, along with alower hazard ratio for survival in cancer patients. Enobosarm waseveluated in the POWER 1(Prevention and Treatment of MuscleWasting in Patients with Cancer)and in the POWER 2 trial. Theseare the first phase 3 trials for a SARM. Full results from thesestudies will soon be published and will guide the development offuture anabolic trials [42].